Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib
January 2016
in “
Journal of clinical biochemistry and nutrition
”
Studysummary In this study, combining deferasirox with sorafenib significantly reduced liver fibrosis and preneoplastic lesions in rats while also lessening adverse effects compared to sorafenib alone.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jstage.jst.go.jp →